| 創建日期 | 上櫃日期 | 董事長 | 總經理 |
|---|---|---|---|
| 105/12/06 | 110/01/08 | 劉銖淇 | 黃文良 |
| EPS | 本益比 | 股價淨值比 | 現金殖利率 |
| 0.68(Q2) | 43.74 | 8.05 | 1.53% |
| 實收資本額 | 已發行普通股 | ||
| 751,987,300 | 75,198,730 | ||
| 主要經營業務 | |||
| 幹細胞產品免疫細胞產品 | |||
| 公司網址 | |||
| ever-supreme.com.tw | |||
長聖(6712) 月營收報表
| 年度/月份 | 營業收入（單位：千元） | 累計營業收入（單位：千元） | |||||
|---|---|---|---|---|---|---|---|
| 單月營收 | 去年同月營收 | 單月月增率 | 單月年增率 | 累計營收 | 去年累計營收 | 累積年增率 | |
| 2023/08 | 78,804 | 57,021 | 30% | 38.2% | 416,230 | 389,656 | 6.8% |
| 2023/07 | 60,604 | 56,518 | 5.8% | 7.2% | 337,426 | 332,635 | 1.4% |
| 2023/06 | 57,304 | 55,103 | 6.1% | 4% | 276,822 | 276,117 | 0.3% |
| 2023/05 | 54,022 | 53,231 | 11.1% | 1.5% | 219,518 | 221,014 | -0.7% |
| 2023/04 | 48,613 | 44,128 | 8.9% | 10.2% | 165,496 | 167,783 | -1.4% |
| 2023/03 | 44,656 | 38,538 | 14.4% | 15.9% | 116,883 | 123,655 | -5.5% |
| 2023/02 | 39,044 | 32,026 | 17.7% | 21.9% | 72,227 | 85,117 | -15.1% |
| 2023/01 | 33,183 | 53,091 | -45.2% | -37.5% | 33,183 | 53,091 | -37.5% |
| 2022/12 | 60,512 | 52,498 | 0.7% | 15.3% | 627,511 | 438,842 | 43% |
| 2022/11 | 60,105 | 51,422 | 1.6% | 16.9% | 566,999 | 386,344 | 46.8% |
| 2022/10 | 59,126 | 51,170 | 1.7% | 15.5% | 506,894 | 334,922 | 51.3% |
| 2022/09 | 58,112 | 50,589 | 1.9% | 14.9% | 447,768 | 283,752 | 57.8% |
| 2022/08 | 57,021 | 48,813 | 0.9% | 16.8% | 389,656 | 233,163 | 67.1% |
| 2022/07 | 56,518 | 44,311 | 2.6% | 27.5% | 332,635 | 184,350 | 80.4% |
| 2022/06 | 55,103 | 36,900 | 3.5% | 49.3% | 276,117 | 140,039 | 97.2% |
| 2022/05 | 53,231 | 30,145 | 20.6% | 76.6% | 221,014 | 103,139 | 114.3% |
| 2022/04 | 44,128 | 24,002 | 14.5% | 83.8% | 167,783 | 72,994 | 129.9% |
| 2022/03 | 38,538 | 19,463 | 20.3% | 98% | 123,655 | 48,992 | 152.4% |
| 2022/02 | 32,026 | 15,650 | -39.7% | 104.6% | 85,117 | 29,529 | 188.2% |
| 2022/01 | 53,091 | 13,879 | 1.1% | 282.5% | 53,091 | 13,879 | 282.5% |
| 2021/12 | 52,498 | 12,859 | 2.1% | 308.3% | 438,842 | 70,597 | 521.6% |
| 2021/11 | 51,422 | 5,133 | 0.5% | 901.8% | 386,344 | 57,738 | 569.1% |
| 2021/10 | 51,170 | 8,086 | 1.1% | 532.8% | 334,922 | 52,605 | 536.7% |
| 2021/09 | 50,589 | 11,676 | 3.6% | 333.3% | 283,752 | 44,519 | 537.4% |
| 2021/08 | 48,813 | 9,381 | 10.2% | 420.3% | 233,163 | 32,843 | 609.9% |
| 2021/07 | 44,311 | 6,081 | 20.1% | 628.7% | 184,350 | 23,462 | 685.7% |
| 2021/06 | 36,900 | 3,748 | 22.4% | 884.5% | 140,039 | 17,381 | 705.7% |
| 2021/05 | 30,145 | 2,043 | 25.6% | 1375.5% | 103,139 | 13,633 | 656.5% |
| 2021/04 | 24,002 | 3,828 | 23.3% | 527% | 72,994 | 11,590 | 529.8% |
| 2021/03 | 19,463 | 2,210 | 24.4% | 780.7% | 48,992 | 7,762 | 531.2% |
| 2021/02 | 15,650 | 2,700 | 12.8% | 479.6% | 29,529 | 5,552 | 431.9% |
| 2021/01 | 13,879 | 2,852 | 7.9% | 386.6% | 13,879 | 2,852 | 386.6% |
| 2020/12 | 12,859 | 4,462 | 150.5% | 188.2% | 70,597 | 10,819 | 552.5% |
| 2020/11 | 5,133 | 2,438 | -36.5% | 110.5% | 57,738 | 6,357 | 808.3% |
| 2020/10 | 8,086 | 1,890 | -30.7% | 327.8% | 52,605 | 3,919 | 1242.3% |
| 2020/09 | 11,676 | 1,029 | 24.5% | 1034.7% | 44,519 | 2,029 | 2094.1% |
評論0